|
注册号: Registration number: |
ChiCTR2500102048 |
|
最近更新日期: Date of Last Refreshed on: |
2025-05-07 18:02:09 |
|
注册时间: Date of Registration: |
2025-05-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
骨质疏松人群与正常人群差异化分析 |
|
Public title: |
Differentiation analysis between the osteoporosis population and the normal population |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
骨质疏松人群与正常人群差异化分析 |
|
Scientific title: |
Differentiation analysis between the osteoporosis population and the normal population |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张增 |
研究负责人: |
刘婷婷 |
|
Applicant: |
Zeng Zhang |
Study leader: |
Tingting Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 178 8988 2359 |
研究负责人电话:
Study leader's |
+86 175 5193 6242 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zzeng66@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xzhhhp765@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
海南省海口市美兰区人民大道58号 |
研究负责人通讯地址: |
海南省海口市美兰区人民大道43号 |
|
Applicant address: |
No. 58, Renmin Avenue, Meilan District, Haikou City, Hainan Province |
Study leader's address: |
No. 43, Renmin Avenue, Meilan District, Haikou City, Hainan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
海南大学 |
||
|
Applicant's institution: |
Hainan University |
||
|
研究负责人所在单位: |
海口市人民医院 |
||
|
Affiliation of the Leader: |
Haikou People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-(伦审)-129 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
海口市人民医院生物医学伦理委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Committee of Haikou City People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-07 00:00:00 | ||
|
伦理委员会联系人: |
邱英麒 |
||
|
Contact Name of the ethic committee: |
Yingqi Qiu |
||
|
伦理委员会联系地址: |
海南省海口市美兰区人民大道43号 |
||
|
Contact Address of the ethic committee: |
No. 43, Renmin Avenue, Meilan District, Haikou City, Hainan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 989 66189770 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
海口市人民医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Haikou City People's Hospital |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
海南省海口市美兰区人民大道43号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
No. 43, Renmin Avenue, Meilan District, Haikou City, Hainan Province |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划研究基金项目(2022YFD2100702) |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
National Key R&D Program of China (2022YFD2100702) |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
骨质疏松症 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Osteoporosis |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
1、比较骨质疏松、骨量减少与正常人群肠道菌群在α/β多样性、菌属组成和代谢功能上的差异 2、鉴定与骨密度(BMD)相关的特征性菌群 3、探索肠道菌群与血清代谢组的关联网络 4、评估基于菌群-代谢标志物的骨质疏松风险预测模型效能 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
1. Compare the differences in α/β diversity, bacterial genus composition and metabolic function of the intestinal microbiota between osteoporosis and osteopenia and the normal population; 2. Identify the characteristic flora related to bone mineral density (BMD); 3. Explore the association network between the intestinal microbiota and the serum metabolome; 4. Evaluate the efficacy of osteoporosis risk prediction models based on microbiota-metabolic markers. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
①有已知骨病、重度营养不良或饮食限制、结肠癌、乳糜泻、内分泌疾病及炎症性肠病史及家族史; ②曾经结肠肠镜检查确诊有肠道器质性疾病; ③近2周内服用过益生菌以及益生菌相关制剂或骨代谢药物和抗生素等; ④曾确诊为心肌梗死、脑梗死、恶性肿瘤等研究者认为不适合入组的严重疾病; ⑤有重大精神疾患,难以控制自己行动,无法配合的受试者; ⑥不识字,无法理解知情同意,无法自行签署知情同意书的受试者。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. History of known bone diseases, severe malnutrition or dietary restrictions, colon cancer, celiac disease, endocrine disorders, inflammatory bowel disease (IBD), or family history of these conditions; 2. Previous diagnosis of organic intestinal diseases confirmed by colonoscopy; 3. Use of probiotics, prebiotic/synbiotic supplements, bone metabolism-affecting medications, or antibiotics within the past 2 weeks; 4. Diagnosed severe comorbidities including myocardial infarction, cerebral infarction, malignant tumors, or other conditions deemed ineligible by investigators; 5. Major psychiatric disorders affecting behavioral control or compliance; 6. Illiteracy, inability to comprehend informed consent, or incapacity to provide written informed consent. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-15 00:00:00至 To 2026-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-07-01 00:00:00 至 To 2025-10-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本试验结束6个月后发表相关研究论文。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
6 months after the trial complete, metadata will be accessed by public via the research papers. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |